Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05090891 · ClinicalTrials.gov registry record · Phase 2
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
A Phase 2 study of Fibrodysplasia Ossificans Progressiva (FOP), sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 98
- Enrollment target
- 20
- Study locations
NCT05090891 is a Phase 2 study of Fibrodysplasia Ossificans Progressiva (FOP) that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 98 participants. The trial reports 20 study locations across 7 states.
The verdict
NCT05090891, a Phase 2 study of Fibrodysplasia Ossificans Progressiva (FOP), is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 98 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase 2, Randomized, Double-Blind, Placebo-Controlled Study is intended to evaluate the Efficacy, Safety, and Tolerability and PK of INCB000928 administered to participants with a clinical diagnosis of fibrodysplasia ossificans progressiva (FOP).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG INCB000928
Study Locations (20)
Other
- Hospital Italiano de Buenos Aires - Ciudad Autonoma Buenos Aires
- Albert Einstein Israelite Hospital - São Paulo
- Centro de Estudios Reumatologicos - Santiago
- Beijing Childrens Hospital Capital Medical University - Beijing
- Tongji Hospital of Tongji University - Shanghai
- Shanghai Childrens Medical Center - Shanghai
- Childrens Hospital of Fudan University - Shanghai
- Ap-Hp Hopital Lariboisiere - Paris
- Hopital Necker-Enfants Malades - Paris
- Uniklinik Koln - Cologne
- Ospedale Pediatrico G. Gaslini - Genova
- Policlinico Universitario Agostino Gemelli Universita Cattolica Del Sacro Cuore - Rome
- Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra - Tlalpan
Pennsylvania
- Children'S Hospital of Philadelphia - Philadelphia
- Penn Medicine - Perelman Center For Advanced Medicine - Philadelphia
California
- University of California San Francisco Medical Center - San Francisco
Minnesota
- Mayo Clinic Rochester - Rochester
New South Wales
- Royal North Shore Hospital - St Leonards
Victoria
- Murdoch Children'S Research Institute - Parkville
Ontario
- University Health Network Toronto General Hospital - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2022-05-05 |
| Est. Completion | 2033-01-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05090891
The ClinicalTrials.gov registry entry for NCT05090891 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fibrodysplasia Ossificans Progressiva (FOP) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05090891 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, Pennsylvania, California.
Frequently Asked Questions
What is clinical trial NCT05090891 about?
NCT05090891 is a clinical study titled "To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva". This Phase 2, Randomized, Double-Blind, Placebo-Controlled Study is intended to evaluate the Efficacy, Safety, and Tolerability and PK of INCB000928 administered to participants with a clinical diagnosis of fibrodysplasia ossificans progressiva (FOP).
What is the current status of trial NCT05090891?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 98 participants. The study started on 2022-05-05. Estimated completion is 2033-01-20.
What conditions does trial NCT05090891 study?
This clinical trial studies the following conditions: Fibrodysplasia Ossificans Progressiva (FOP).
What interventions are being tested in trial NCT05090891?
The interventions under investigation include: Placebo (DRUG), INCB000928 (DRUG).
Who is sponsoring clinical trial NCT05090891?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05090891 being conducted?
This trial has 20 study locations across California, Minnesota, Pennsylvania, New South Wales, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fibrodysplasia Ossificans Progressiva (FOP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.